The handle  http://hdl.handle.net/1887/68643 holds various files of this Leiden University dissertation.

**Author:** Pardi, D.J.
**Title:** Exploring the relationships of gamma-hydroxybutyrate and sleep on metabolism, physiology, and behavior in humans
**Issue Date:** 2019-01-24
CHAPTER 7

Plasma Total Ghrelin and Leptin Levels in Human Narcolepsy and Matched Healthy Controls: Basal Concentrations and Response to Sodium Oxybate

*Journal of Clinical Sleep Medicine (2013) 9(8):797-803*

**Authors:** Daniel Pardi, Claire E.H.M. Donjacour, N. Ahmad Aziz, Marijke Frölich, Ferdinand Roelfsema, Sebastiaan Overeem, Hanno Pijl and Gert Jan Lammers
## Abstract

### Study Objective

Narcolepsy is caused by a selective loss of hypocretin neurons and is associated with obesity. Ghrelin and leptin interact with hypocretin neurons to influence energy homeostasis. Here, we evaluated whether human hypocretin deficiency, or the narcolepsy therapeutic sodium oxybate, alter the levels of these hormones.

### Methods

Eight male, medication free, hypocretin deficient, narcolepsy with cataplexy patients, and 8 healthy controls matched for age, sex, body mass index (BMI), waist-to-hip ratio, and body fat percentage were assessed. Blood samples of total ghrelin and leptin were collected over 24 hours at 60 and 20-min intervals, respectively, during two study occasions: baseline, and during the last night of 5 consecutive nights of sodium oxybate administration (2 x 3.0g/night).

### Results

At baseline, mean 24-h total ghrelin (936 ± 142 vs. 949 ± 175 pg/mL, \( p = 0.873 \)) and leptin (115 ± 5.0 vs. 79.0 ± 32 mg/L, \( p = 0.18 \)) levels were not different between hypocretin deficient narcolepsy patients and controls. Furthermore, sodium oxybate did not significantly affect the plasma concentration of either one of these hormones.

### Conclusion

The increased BMI of narcolepsy patients is unlikely to be mediated by hypocretin deficiency-mediated alterations in total ghrelin or leptin levels. Thus, the effects of these hormones on hypocretin neurons may be mainly unidirectional. Although sodium oxybate may influence body weight, the underlying mechanism is unlikely to involve changes in total ghrelin or leptin secretion.
Introduction

The hypocretin system, also known as the orexin system, is of major importance in the regulation of sleep and sustained wakefulness. Moreover, hypocretin neurons are responsive to metabolites and hormones helping to translate signals of metabolic state into adaptive levels of activity and consciousness. Hypocretin deficiency leads to narcolepsy, a sleep-wake disorder characterized by excessive daytime sleepiness, cataplexy, and disrupted nocturnal sleep. Obesity is associated with the disorder, yet the cause of the increased body weight has been challenging to discern due to inconsistent findings on the hormonal and metabolic characteristics of this population. However, altered ingestive behavior has been consistently observed in these patients, suggesting hypocretin deficiency may dysregulate feeding behavior, and possibly energy homeostasis.

Ghrelin is a peptide hormone mainly produced by endocrine cells in the stomach and gastrointestinal tract, and is an important endogenous regulator of energy balance and growth hormone (GH) secretion. Its expression is complex and influenced by sympathetic nervous system activity. Across the wake period, plasma concentration wax and wane episodically providing an orexigenic signal to the brain. During sleep, ghrelin levels increase in the early part of the night and decrease towards morning, however, this nocturnal increase is blunted during sleep deprivation. Hypocretin neurons directly sense and are excited by ghrelin and an interaction between these two systems has been shown to be involved in ingestive behavior. A study by Toshinai et al. first identified this connection. In that study, ghrelin-induced feeding was attenuated in rats pretreated with anti-hypocretin-1 IgG and anti-hypocretin-2 IgG and suppressed in hypocretin-knockout mice. Later, it was demonstrated that ghrelin plays a key role in the rewarding aspects of eating, but it requires the presence of intact hypocretin signaling to impart this effect.

Leptin is another peptide hormone involved in energy homeostasis, the dominant role of which is to signal energy deficiency to the brain. It is an adipokine produced primarily by subcutaneous white adipose tissue and its expression is stimulated by various hormones, sympathetic outflow, energy intake and output. Under normal conditions, blood levels display circadian variation as levels rise across the day and peak in the middle of the night. During sleep deprivation, blood leptin levels show a reduced and flattened profile. Receptors for leptin are found on hypocretin cells and leptin can directly inhibit the expression of isolated hypocretin neurons. Indirectly, leptin can affect the activity of hypocretin cells via energy-regulating neurons in the arcuate nucleus of the hypothalamus. Conversely, because the hypocretin system greatly influences autonomic control, it is plausible that hypocretin deficiency may alter leptin expression via inhibited sympathetic activity. Indeed, obese hypocretin deficient mice have lowered sympathetic vasoconstrictor outflow, while greater heart rate variability has been observed in hypocretin deficient narcolepsy patients. Thus, leptin and hypocretin may interact to affect levels of physical activity and wakefulness in response to energy needs, and the loss of hypocretin neurons may dysregulate leptin expression and signaling.
While ghrelin levels have not been previously reported in hypocretin-deficient narcoleptic patients, abnormal leptin levels have been observed.\textsuperscript{4, 5} It is unknown if the associations between hypocretin and total ghrelin or leptin are uni-or-bidirectional. Because hypocretin influences sympathetic outflow, and sympathetic nervous system activity effects the expression of both leptin and ghrelin, hypocretin deficiency may lead to altered levels of these hormones. This study of hypocretin-deficient narcoleptic patients provides a unique opportunity to further explore the nature of these relationships. We hypothesize both total ghrelin and leptin levels will be abnormal in hypocretin-deficient narcolepsy patients, which may help explain the increased BMI and abnormal ingestive behavior seen in this population.\textsuperscript{5, 7, 8, 29-31}

Additionally, we explored if the narcolepsy therapeutic,\textsuperscript{48} sodium oxybate, has an effect on these hormones. In a narcolepsy population, sodium oxybate improves disrupted nocturnal sleep, impaired wakefulness, and cataplexy, and promotes weight loss.\textsuperscript{32, 33} Like ghrelin, sodium oxybate administration also stimulates GH release.\textsuperscript{34} We hypothesize that its administration will alter total ghrelin levels, the effect of which may be involved in its GH-promoting effects.

Here, we investigate whether total blood ghrelin or leptin levels are altered in hypocretin-deficient narcoleptic patients compared to controls, and whether total ghrelin or leptin levels are influenced by sodium oxybate.

**Materials and methods**

**Subjects**

We included eight medication free, male hypocretin deficient narcolepsy with cataplexy patients and eight healthy male controls, matched for age, BMI and body fat percentage. Hypocretin measurement was performed according to international standards.\textsuperscript{35} Body fat percentage was measured with bioelectrical impedance analysis (Bodystat, Douglas, Isle of Man, UK). Two patients were drug naive, one patient was tapered from antidepressants at least two weeks prior to the study, and two patients had prior history with sodium oxybate therapy; however, no subject took sodium oxybate within 20 days of study initiation. The other patients did not take any medication for at least several months prior to beginning the study.

Subjects were eligible for participation after exclusion of chronic conditions, with particular attention to the absence of sleep disorders in control subjects, hypertension, pituitary disease, and weight change (>4% kg weight gain or loss within the last 3 months) as assessed by structured clinical interview. None of the participants had previously undergone gastrectomy. Written informed consent was obtained from all subjects. The study was approved by the ethics committee of the Leiden University Medical Center.
Clinical protocol

All subjects were admitted to the Clinical Research Center for 24-h blood sampling before and after 5 days of sodium oxybate administration. A cannula was inserted into an antecubital vein at least 45 minutes before the start of blood sampling at 1200 h. Blood samples were collected with 5-monovetten (Sarstedt, Etten-Leur, The Netherlands) from a three-way stopcock that was attached to a 0.9% NaCl and heparin (1 U/ml) infusion (750 ml/24 h) to keep the cannula from clotting. For total ghrelin measurements, blood was collected in EDTA tubes at 60-min intervals and these tubes were immediately put on ice. Ghrelin samples were acidified with 50 µl of 1 N HCL. Within 5 minutes of sampling, tubes were centrifuged at 1250 g at 4 °C for 20 minutes. For Leptin measurements, blood was collected at 20-min intervals. After clotting, the blood was centrifuged within 30 minutes of sampling (20 minutes, 1250 g, 4 °C). Serum was then stored at -80 °C until hormonal assays. Three standardized meals were served at 0830, 1300, and 1800 h (Nutridrink, 1.5 kcal/ml, 2100 kcal/d; macronutrient composition per 100 ml: protein, 6 g; fat, 5.8 g; carbohydrate, 18.4 g; Nutricia, Zoetermeer, The Netherlands). Subjects were asked to complete each meal provided. Food-induced suppression of total ghrelin release was defined as the ratio between total ghrelin levels one hour postprandially to the levels immediately before the meal (lunch and dinner) or 30 min postprandially to 30 min before the meal (breakfast). Subjects remained sedentary except for bathroom visits. In both study occasions, lights were switched off (dark period) at 2300 h and then switched on at 0730 h.

Sodium oxybate

In the drug-intervention study occasion, sodium oxybate was administered in a total nightly dose of 6 grams per night for 5 consecutive nights in both the narcoleptic patients and the controls. Each night, 3 grams of sodium oxybate were administered orally at 2300 h and 0300 h. Lights were turned off after ingestion of the first dose.

Sleep recordings

During the 24-hour sampling periods, polysomnographic recordings were performed using an ambulant EEG-recording system (Embletta X100, Embla) and a standard EEG/EMG montage to allow sleep scoring according to the AASM-criteria. Using a marker-tool, the start of the sampling protocol was registered to synchronize sleep-recordings with hormone measurements. Sleep recordings were scored by an experienced technician, blinded for the subject under study.

Assays

Plasma total ghrelin and leptin levels were measured by radioimmunoassay (LINCO Research, St. Charles, MO, USA) with a detection limit of 93 pg/mL, and an interassay variation ranging from 14.7 to 17.8% for total ghrelin and a detection limit of 0.5 µg/L and an interassay variation ranging from 3.0 to 5.1% for leptin. Samples from each patient and matched control were handled in the same run.
Deconvolution analysis

Leptin concentration time series were analyzed via a recently developed automated deconvolution method, empirically validated using hypothalamo-pituitary sampling and simulated pulsatile time series. The MATLAB-based algorithm first detrends the data and normalizes concentrations to the unit interval [0, 1]. Second, the program creates multiple successive potential pulse-time sets, each containing one fewer burst via a smoothing process (a nonlinear adaptation of the heat-diffusion equation). Third, a maximum-likelihood expectation estimation method computes all secretion and elimination parameters simultaneously conditional on each of the multiple candidate pulse-time sets. The fast half-life was represented as 3.4 min constituting 19% of the decay amplitude. The slow half-life was estimated as an unknown variable between 6 and 70 min. Here we present only results for pulse frequency (pulses per 24 h), basal secretion, pulsatile secretion and total secretion per 24 h, all expressed as µg per liter distribution volume.

Data analysis and statistics

Results are expressed as mean ± standard deviation (SD). Unpaired t-tests were used to assess differences in means between the two groups, while paired t-tests were applied to assess changes in means within each group. All tests were two-tailed, and significance level was set at p < 0.05. Statistical analyses were performed using SPSS for Windows (release 17.0, SPSS, Inc., Chicago, IL).

Results

Subjects

Patients and controls did not differ with respect to age, BMI, waist-to-hip ratio, and body fat percentage (Table 1). Sodium oxybate was well tolerated by all participants. Apart from mild drowsiness, no other side-effects were reported during the study.

TABLE 1. Demographics, body composition, baseline parameters

<table>
<thead>
<tr>
<th></th>
<th>Patients</th>
<th>Controls</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>38.0 ± 13.4</td>
<td>37.9 ± 11.6</td>
<td>0.984</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.1 ± 4.6</td>
<td>27.4 ± 4.0</td>
<td>0.742</td>
</tr>
<tr>
<td>Waist/hip ratio</td>
<td>0.92 ± 0.10</td>
<td>0.90 ± 0.04</td>
<td>0.579</td>
</tr>
<tr>
<td>Body fat (%)</td>
<td>23.6 ± 6.0</td>
<td>23.4 ± 4.8</td>
<td>0.946</td>
</tr>
</tbody>
</table>

Data are shown as mean ± standard deviation.

Sleep and wakefulness differences

When compared to controls, during baseline conditions and after sodium oxybate administration, narcolepsy patients spent significantly less time awake across a 24 h period, and during the day (defined as the lights-on period between 0730 h-2300
h) they spent less time awake and more time in slow wave sleep (SWS) \( (p = 0.004 \) and \( p = 0.005 \), respectively) (Table 2).

**TABLE 2.** Sleep patterns before and after sodium oxybate administration

<table>
<thead>
<tr>
<th></th>
<th>Narcolepsy</th>
<th>Controls</th>
<th>Narcolepsy vs. controls (baseline)</th>
<th>Narcolepsy vs. controls (SXB)</th>
<th>Treatment effect</th>
<th>Interaction (group × treatment)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wake total (%)</strong></td>
<td>60.8 ± 2.9</td>
<td>60.8 ± 2.2</td>
<td>68.7 ± 2.0</td>
<td>70.1 ± 2.4</td>
<td>0.044*</td>
<td>0.013*</td>
</tr>
<tr>
<td><strong>Sleep day (%)</strong></td>
<td>79.4 ± 4.2</td>
<td>82.9 ± 3.2</td>
<td>95.6 ± 2.1</td>
<td>97.3 ± 1.0</td>
<td>0.004**</td>
<td>0.001**</td>
</tr>
<tr>
<td><strong>Sleep night (%)</strong></td>
<td>25.8 ± 5.7</td>
<td>19.2 ± 4.3</td>
<td>18.4 ± 4.0</td>
<td>19.2 ± 5.8</td>
<td>0.31</td>
<td>1.00</td>
</tr>
<tr>
<td><strong>Stage I/II total (%)</strong></td>
<td>29.1 ± 1.4</td>
<td>26.3 ± 1.4</td>
<td>25.0 ± 2.4</td>
<td>21.1 ± 2.2</td>
<td>0.16</td>
<td>0.063</td>
</tr>
<tr>
<td><strong>Stage I/II day (%)</strong></td>
<td>14.6 ± 3.0</td>
<td>11.1 ± 2.5</td>
<td>2.5 ± 1.6</td>
<td>1.6 ± 1.0</td>
<td>0.003**</td>
<td>0.005**</td>
</tr>
<tr>
<td><strong>Stage I/II night (%)</strong></td>
<td>55.1 ± 2.5</td>
<td>53.5 ± 3.7</td>
<td>65.6 ± 5.7</td>
<td>56.4 ± 5.3</td>
<td>0.11</td>
<td>0.65</td>
</tr>
<tr>
<td><strong>SWS total (%)</strong></td>
<td>3.7 ± 0.7</td>
<td>7.6 ± 1.2</td>
<td>2.5 ± 0.7</td>
<td>6.6 ± 0.9</td>
<td>0.24</td>
<td>0.53</td>
</tr>
<tr>
<td><strong>SWS day (%)</strong></td>
<td>2.1 ± 0.6</td>
<td>2.7 ± 1.1</td>
<td>0.03 ± 0.03</td>
<td>0.05 ± 0.05</td>
<td>0.005**</td>
<td>0.041*</td>
</tr>
<tr>
<td><strong>SWS night (%)</strong></td>
<td>6.5 ± 1.9</td>
<td>16.5 ± 3.0</td>
<td>7.1 ± 1.9</td>
<td>18.5 ± 2.4</td>
<td>0.84</td>
<td>0.61</td>
</tr>
<tr>
<td><strong>REM total (%)</strong></td>
<td>6.3 ± 1.8</td>
<td>4.7 ± 1.0</td>
<td>3.7 ± 0.8</td>
<td>2.1 ± 0.8</td>
<td>0.19</td>
<td>0.070</td>
</tr>
<tr>
<td><strong>REM day (%)</strong></td>
<td>2.9 ± 1.4</td>
<td>1.2 ± 0.5</td>
<td>0.8 ± 0.5</td>
<td>0.0 ± 0.0</td>
<td>0.20</td>
<td>0.032*</td>
</tr>
<tr>
<td><strong>REM night (%)</strong></td>
<td>12.6 ± 3.0</td>
<td>10.8 ± 2.1</td>
<td>8.8 ± 1.8</td>
<td>5.8 ± 2.3</td>
<td>0.31</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>No. of awakenings</strong></td>
<td>50.5 ± 10.5</td>
<td>35.0 ± 4.8</td>
<td>35.5 ± 7.1</td>
<td>15.3 ± 1.7</td>
<td>0.26</td>
<td>0.005**</td>
</tr>
<tr>
<td><strong>Sleep efficiency (%)</strong></td>
<td>66.9 ± 7.0</td>
<td>81.5 ± 4.9</td>
<td>81.2 ± 4.0</td>
<td>81.9 ± 6.0</td>
<td>0.10</td>
<td>0.96</td>
</tr>
</tbody>
</table>

Percentages of sleep stages during the 24 hours of study, before and after SXB administration. Data are shown as mean ± SEM. Unpaired t tests were used to assess differences between the two groups. Mixed-effects models were applied to assess the effect of treatment and potential interaction effects between group (i.e. narcolepsy or control) and treatment. * \( p < 0.05 \) and ** \( p < 0.01 \).
TABLE 3. Plasma ghrelin concentrations and deconvolution of leptin levels before and after administration of sodium oxybate in both narcoleptic patients and controls

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Sodium Oxybate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients</td>
<td>Controls</td>
</tr>
<tr>
<td>Ghrelin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24-h total integrated concentration (pg/mL)</td>
<td>936 ± 142</td>
<td>949 ± 175</td>
</tr>
<tr>
<td>Dark perioda(pg/mL)</td>
<td>1012 ± 156</td>
<td>1009 ± 196</td>
</tr>
<tr>
<td>Food induced suppression of ghrelin concentrationb (pg/mL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lunch</td>
<td>0.83 ± 0.10</td>
<td>0.86 ± 0.09</td>
</tr>
<tr>
<td>Dinner</td>
<td>0.93 ± 0.16</td>
<td>0.83 ± 0.17</td>
</tr>
<tr>
<td>Breakfast</td>
<td>1.05 ± 0.10</td>
<td>1.01 ± 0.09</td>
</tr>
<tr>
<td>Postprandial total ghrelinc (pg/mL)</td>
<td>0.93 ± 0.08</td>
<td>0.90 ± 0.11</td>
</tr>
<tr>
<td>Leptin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total 24-h secretion (µg/Lx24h)</td>
<td>115 ± 98</td>
<td>79.0 ± 88</td>
</tr>
<tr>
<td>Basal 24-h secretion (µg/Lx24h)</td>
<td>64.7 ± 63</td>
<td>37.9 ± 30</td>
</tr>
<tr>
<td>Pulsatile 24-h secretion (µg/Lx24h)</td>
<td>50.3 ± 36</td>
<td>25.6 ± 11</td>
</tr>
<tr>
<td>Pulse frequency (no/24h)</td>
<td>18.5 ± 2.7</td>
<td>15.3 ± 4.8</td>
</tr>
</tbody>
</table>

a In both study occasions, lights were switched off (dark period) at 2300 h and then switched on at 0730 h
b Expressed as the ratio between post- to preprandial ghrelin concentration
c Averaged over three occasions

Effect of sodium oxybate administration on sleep and wakefulness

In both groups, administration of sodium oxybate resulted in a significant decrease in stages I/II non-rapid eye movement (REM) and REM sleep over 24 hours (p = 0.011 and p = 0.009, respectively), while at night, awakenings were significantly reduced (p = 0.002) and the percentage of SWS more than doubled (narcolepsy: 6.5 ± 5.5 % vs. 16.5 ± 8.4 %, controls: 7.1 ± 5.5 % vs. 18.5 ± 6.4 %; p = 0.001 for administration effect). During the day, time spent in stages I/II non-REM and REM
sleep ($p = 0.038$ and $p = 0.041$, respectively) was reduced, while there was a trend towards longer periods of wakefulness ($p = 0.098$).

**Baseline total ghrelin levels**

Mean 24-h total ghrelin levels at baseline were virtually identical between narcolepsy patients and controls ($p = 0.873$; Fig. 1A). Mean total ghrelin levels were also not different between the two groups when the analyses were restricted to the dark period ($p = 0.973$). In fact, at no single time-point an intergroup difference could be detected (all $p \geq 0.232$). Food induced suppression of total ghrelin concentration (expressed as the ratio between post- to preprandial total ghrelin concentration) was similar in the two groups (lunch: $p = 0.413$, dinner: $p = 0.301$, breakfast: $p = 0.437$, and mean postprandial total ghrelin levels averaged over the three occasions ($p = 0.540$) (Table 3).
FIGURE 1. Mean 24 h ghrelin levels in narcolepsy patients and matched controls. The diurnal plasma ghrelin levels, as well as food induced suppression of ghrelin release were not significantly different between narcolepsy patients and matched controls, either during basal conditions (A) or after five days of sodium oxybate administration (B). Hourly blood sampling started at noon and continued for 24 hours. The black bar on the abscissa indicates the dark period (2300-0730 h). The grey arrows indicate the timings of the lunch, dinner and breakfast at 1300 h, 1800 h and 0830 h, respectively. The black arrows indicate the timings of sodium oxybate administrations during the second study occasion at 2300 h and 0300 h.

Effect of sodium oxybate on total ghrelin levels

Twenty-four hour mean total ghrelin levels during sodium oxybate treatment were not different between narcolepsy patients and controls ($p = 0.642$; Fig. 1B). Similar to baseline, mean total ghrelin levels during the dark period did not differ between the two groups ($p = 0.449$), and at no single time-point a difference could be
detected between groups (all \( p \geq 0.05 \)). Postprandial total ghrelin suppression, as defined above, was also similar between the two groups after sodium oxybate administration: lunch \((p = 0.920)\), dinner \((p = 0.261)\), and breakfast \((p = 0.880)\); mean postprandial total ghrelin levels averaged over the three occasions \((p = 0.428)\) (Table 3). The average change in 24 h total ghrelin levels between the second and first occasion amounted to \(-15 \pm 72 \text{ pg/ml}\) in narcolepsy patients and \(-63 \pm 87 \text{ pg/ml}\) in controls but was not significantly different from zero in either group (paired t-tests: \( p = 0.56 \) and \( p = 0.078 \), respectively).

**FIGURE 2.** Mean 24-h plasma leptin concentration ± SD, before (A) and during sodium oxybate administration (B) in narcolepsy patients and matched controls. The black horizontal bar on the abscissa indicates the lights off period. The grey arrows indicate the timing of meals and the black arrows indicate timing of sodium oxybate administration (B).
Baseline leptin levels

Mean 24-h total leptin levels at baseline were not significantly different between narcolepsy patients and controls ($p = 0.18$; Fig. 2A). Mean pulse frequency was different between the two groups ($p = 0.04$) but mean 24-h basal and pulsatile secretion levels were not different ($p = 0.96$; $p = 0.11$, respectively) (Table 3).

Effect of sodium oxybate on leptin levels

Mean 24-h total leptin levels during sodium oxybate treatment were not significantly different between narcolepsy patients and controls ($p = 0.58$; Fig. 2B) and neither were mean 24-h basal and pulsatile secretion rates ($p = 0.94$; $p = 0.29$, respectively). Mean pulse frequency was different between the two groups ($p = 0.04$) (Table 3).

Discussion

We found no differences in mean 24-h total plasma ghrelin levels or food-induced suppression of ghrelin concentrations between narcolepsy patients and controls, nor any influence of 5 days of sodium oxybate administration in both groups. In view of the capacity of ghrelin to stimulate growth hormone secretion, it is worth noting that a report from this same research protocol showed no differences in mean hourly GH levels between patients and controls, supporting our conclusion that total ghrelin levels are not altered with hypocretin deficiency.\(^{37}\)

Despite the excitatory influence of ghrelin on hypocretin neurons, and the interaction of the ghrelin-hypocretin systems to influence food reinforcement, our finding did not show the total ghrelin level to be influenced by hypocretin deficiency, suggesting a unidirectional relationship. These findings also suggest that disturbed ingestive behavior is unlikely mediated by an altered total ghrelin level in narcolepsy patients. Notably, we measured total ghrelin levels and not the biologically active, octanoylated-ghrelin fraction. While there is a high correlation between the total and octanoylated fraction ghrelin level,\(^{38}\) it remains possible that the active fraction may be altered in this population.

In contrast to earlier reports,\(^4,^5\) more recent, larger, controlled studies have not demonstrated an abnormal leptin level in humans with hypocretin deficiency.\(^6,^39\) Similar to the recent research on this subject, we found that the mean 24-h total leptin level, and basal and pulsatile secretion levels were not significantly different between narcolepsy patients and controls. The mean leptin pulse frequency was slightly but significantly higher in narcolepsy patients in both conditions, but the clinical relevance of this finding is unclear. Because sleep disruption and insulin resistance\(^40\) have been shown to affect leptin levels, it is plausible that previous investigations showing decreased leptin in narcolepsy may have resulted from a study sample of narcoleptic patients with relatively poor sleep or a difference in insulin sensitivity compared to the control group.

There were several limitations to the study. The small number of patients and controls raise the possibility of a type II statistical error. However, the intergroup
differences were very small therefore a large sample size would be needed to
detect a difference if present. Since sleep-wake state instability is intrinsic to
hypocretin-deficiency, standardizing research parameters such as study
environment, meal timing and composition, and predefined bed times may have
created a setting not representative of real-life conditions for these patients.
Therefore, although we did not find alterations in total ghrelin and leptin
concentrations in this controlled and standardized environment, it remains
possible that the release of these hormones is affected by the altered sleep, wake,
and eating patterns described in this population.

As expected, in both groups’ nighttime administration of sodium oxybate increased
SWS and reduced awakenings, and the narcoleptic-patient group showed a trend
towards increased wakefulness the following day. As demonstrated in other
studies, sodium oxybate administration corresponds with a significant increase
in GH release. However, we found no evidence that the GH-elevating effect
is mediated through an influence on total ghrelin secretion. Although, the
difference in total ghrelin levels between patients and controls after sodium
oxybate administration was not significant, it is possible that significant differences
would be seen with higher doses, prolonged periods of nightly administration or in
a larger group of subjects. Lastly, we did not see an effect of sodium oxybate on
the leptin level and to our knowledge, an interaction between this drug and
hormone has not been reported elsewhere.

Therefore, mechanisms underlying increased BMI and altered ingestive behavior
in narcolepsy, and the effects of sodium oxybate administration on GH release and
weight loss, are unlikely to involve changes in total plasma ghrelin or leptin
concentrations. Future investigations should further evaluate if the sleep-wake
instability intrinsic to hypocretin-deficient narcolepsy promotes ingestive and
activity patterns that promote positive energy balance.

Acknowledgements
We thank E.J.M. Ladan-Eygenraam, M. van Dijk-Besling, H.G. Haasnoot-van der
Bent, J. van Vliet-de Regt and P.J. van Someren for technical assistance throughout
the study.

Support
This study was supported by an unrestricted grant from UCB Europe.
Disclosures

- Claire E.H.M. Donjacour, MD has no relevant financial relationships or relations with a commercial interest.
- Daniel Pardi, MS was previously employed with Jazz Pharmaceuticals and has consulted with UCB Europe.
- N. Ahmad Aziz, MSc has no relevant financial relationships or relations with a commercial interest.
- Marijke Frölich, MD, PhD has no relevant financial relationships or relations with a commercial interest.
- Ferdinand Roelfsema, MD, PhD has no relevant financial relationships or relations with a commercial interest.
- Sebastiaan Overeem, MD, PhD has consulted for and received honoraria as a speaker from UCB Europe
- Hanno Pijl, MD, PhD has no relevant financial relationships or relations with a commercial interest.
- Gert Jan Lammers, MD, PhD is member of the international advisory board on narcolepsy for UCB and received honoraria as a speaker from UCB

References


2. Sakurai T. Roles of orexins and orexin receptors in central regulation of feeding behavior and energy homeostasis. CNS Neurol Disord Drug Targets 2006;5:313-25.


32. Pardi D, Black J. gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. CNS Drugs 2006;20:993-1018.


